v3.20.2
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue
Expenses:        
Research and development 7,519 4,751 20,319 11,582
General and administrative 5,775 2,276 20,690 7,391
Operating expenses 13,294 7,027 41,009 18,973
Other income (expense):        
Interest income 46 187 485 407
Foreign exchange losses (1) (4) (1) (2)
Total other income 45 183 484 405
Net loss (13,249) (6,844) (40,525) (18,568)
Other comprehensive gain/(loss):        
Unrealized gain/(loss) on securities available-for-sale (2) (5) (17) 13
Total comprehensive loss $ (13,251) $ (6,849) $ (40,542) $ (18,555)
Basic and diluted loss per common share (in dollars per share) $ (0.15) $ (0.12) $ (0.51) $ (0.39)
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (in thousands) (in shares) 85,860 55,454 79,477 47,315

Source